Full-Time

Associate Director

Product Quality

Confirmed live in the last 24 hours

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops therapies using targeted protein degradation

Biotechnology
Healthcare

Senior, Expert

Belmont, MA, USA

Hybrid work model with a minimum of 3 days/week in the office.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary

You match the following Kymera Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor of Science in Life Sciences
  • 8 + years of experience in pharmaceutical manufacturing or laboratory settings
  • At least 4 years in a GMP quality assurance role
  • Experience in Quality oversight of outsourced GMP manufacturing activities
  • Excellent communication and interpersonal skills
  • Experience working in a CMC team setting as a Quality representative
  • Strong problem-solving ability to evaluate quality matters and make risk-based decisions
Responsibilities
  • Provide quality oversight of contract organizations associated with the manufacturing and distribution of clinical APIs, Drug Products, and Finished Goods
  • Collaborate with manufacturing and distribution colleagues to review manufacturing batch records, protocols, reports, and specifications, and perform disposition of critical intermediates, drug substances/drug products, and finished goods
  • Partner closely with CMC analytical colleagues to review test methods, SOPs, analytical data summaries, validation and stability protocols, and technical reports, and oversee specification control and shelf life management
  • Ensure that product quality-related issues, including deviations/OOSs/OOTs and product complaints, are appropriately investigated and resolved
  • Collaborate cross-functionally and develop strong relationships with internal and external partners
  • Support the preparation and review of regulatory filing submissions (IND/IMPD/NDA)
  • Help develop and implement phase-appropriate SOPs and policies, ensuring compliance with relevant regulatory requirements such as FDA, EMA, and ICH guidelines
  • Manage the qualification and performance monitoring of external GMP suppliers and maintain Quality Agreements with them
  • Develop and track quality metrics to measure performance and identify trends
  • Present quality assessments to the Material Review Board and Quality Management Review Board
Desired Qualifications
  • Experience in a small-molecule manufacturing environment is preferred

Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to enhance their research and development efforts.

Company Size

201-500

Company Stage

IPO

Total Funding

$191.6M

Headquarters

Cambridge, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Kymera raised $225M and $275M in public offerings, boosting financial resources.
  • HSBC's investment indicates strong confidence in Kymera's business model and prospects.
  • Partnership with Neosphere Biotechnologies opens new therapeutic opportunities in molecular glue discovery.

What critics are saying

  • Increased competition in protein degradation could impact Kymera's market share.
  • Regulatory scrutiny may delay clinical trials and drug approval timelines.
  • Dependence on key partnerships like Sanofi could affect revenue if altered.

What makes Kymera Therapeutics unique

  • Kymera's Pegasus Platform enables precise identification and degradation of disease-causing proteins.
  • The company focuses on targeted protein degradation, a novel approach in drug development.
  • Kymera's strategic partnership with Sanofi enhances its credibility and market reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

0%
Yahoo Finance
Aug 20th, 2024
Kymera Therapeutics Announces Pricing of $225 Million Public Offering

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock

Endpoints News
Aug 20th, 2024
Kymera seeks to raise $225M; Adcendo, Multitude's new ADC deal

Kymera Therapeutics aims to raise $225M: The public offering will be...

TXBN
Aug 20th, 2024
Kymera seeks to raise $225M; Adcendo, Multitude's new ADC deal

Kymera Therapeutics aims to raise $225M: The public offering will be used to fund Kymera's pipeline, and some funds could be used for small acquisitions or in-licensing deals.

BioWorld
May 14th, 2024
Neosphere Biotechnologies and Kymera Therapeutics partner to advance molecular glue target discovery

Neosphere Biotechnologies and Kymera Therapeutics partner to advance molecular glue target discovery.

Enid News & Eagle
May 2nd, 2024
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

Kymera unveiled its first-in-class oral TYK2 degrader, KT-294, at its Immunology R&D Day in January 2024.

Defense World
Mar 11th, 2024
Hsbc Holdings PLC Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Hsbc Holdings PLC makes new investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR).

BioSpace
Feb 15th, 2024
Kymera Therapeutics To Report Fourth Quarter And Full Year 2023 Financial Results On February 22

WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET.To access the February 22 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company’s conference call will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.About Kymera Therapeutics

MarketScreener
Jan 5th, 2024
Kymera Therapeutics Announces Pricing of $275 Million Public Offering

Kymera Therapeutics announces pricing of $275 million public offering.

MarketScreener
Jan 5th, 2024
Kymera Therapeutics Announces Pricing of $275 Million Public Offering

WATERTOWN, Mass., Jan. 05, 2024 -- Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation ,...

Benzinga
Jan 4th, 2024
Kymera Therapeutics Announces Proposed Public Offering - Kymera Therapeutics (NASDAQ:KYMR)

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein